Rubicon Research Stock Price Today (NSE: RUBICON)
Fundamental Score
Rubicon Research Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Rubicon Research share price today is ₹1302.60, up +11.23% on NSE/BSE as of 19 June 2026. Rubicon Research (RUBICON) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹10.55K (Cr). The 52-week high for RUBICON share price is ₹1370.00 and the 52-week low is ₹570.75. At a P/E ratio of 68.60x, RUBICON is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 29.02% and a debt-to-equity ratio of 0.88.
Rubicon Research Share Price Chart — NSE/BSE Historical Performance
Rubicon Research share price chart: 1.05% return over the past month. 52-week high ₹1370.00, 52-week low ₹570.75.
Rubicon Research — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1215.00 | ₹1370.00 | ₹1175.10 | ₹1302.60 | 80.62L (Cr) | |
| ₹1044.30 | ₹1206.70 | ₹1044.30 | ₹1171.10 | 38.38L (Cr) | |
| ₹984.00 | ₹1020.00 | ₹968.00 | ₹1005.60 | 2.91L (Cr) | |
| ₹967.90 | ₹967.90 | ₹967.90 | ₹967.90 | 0.00 (Cr) | |
| ₹988.00 | ₹988.00 | ₹957.10 | ₹967.90 | 77.95K (Cr) | |
| ₹944.00 | ₹985.00 | ₹944.00 | ₹977.75 | 1.38L (Cr) | |
| ₹959.00 | ₹963.15 | ₹940.15 | ₹944.55 | 89.95K (Cr) | |
| ₹978.55 | ₹978.70 | ₹945.15 | ₹949.75 | 1.14L (Cr) | |
| ₹986.10 | ₹998.75 | ₹965.00 | ₹969.10 | 96.57K (Cr) | |
| ₹977.60 | ₹999.00 | ₹965.00 | ₹986.05 | 1.65L (Cr) |
Rubicon Research — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1044.30 | ₹1370.00 | ₹1044.30 | ₹1302.60 | +24.73% | |
| ₹970.00 | ₹1020.00 | ₹918.00 | ₹1005.60 | +3.67% | |
| ₹775.55 | ₹983.20 | ₹762.45 | ₹969.95 | +25.07% | |
| ₹773.10 | ₹820.40 | ₹732.05 | ₹772.80 | -0.04% | |
| ₹675.65 | ₹822.00 | ₹665.90 | ₹780.35 | +15.50% | |
| ₹672.30 | ₹697.05 | ₹625.00 | ₹684.25 | +1.78% | |
| ₹658.50 | ₹704.65 | ₹609.25 | ₹680.75 | +3.38% | |
| ₹620.00 | ₹754.80 | ₹607.15 | ₹655.85 | +5.78% | |
| ₹620.00 | ₹639.70 | ₹570.75 | ₹618.15 | -0.30% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Rubicon is an expensive, promoter-selling roll-up story trading on hope, not fundamentals.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Rubicon Research is acquiring an 85% stake in Arinna Lifesciences for , valuing Arinna at an enterprise value of The deal, announced on April 15, 2026, gives Rubicon access to the Indian CNS formulations market. Q3 FY26 consolidated net profit climbed 91.2% to , with revenue up 51.73% to YoY.
CORE STORY (THE REAL GAME)
Rubicon is betting on the India CNS market via inorganic expansion, aiming to leverage Arinna's distribution network and product portfolio to accelerate growth. It's an India-play, not just a regulated markets story.
- Arinna acquisition provides immediate CNS market access
- Strong Q3 FY26 earnings growth
- Analyst target price upgrade
- Successful integration of Arinna
- Faster-than-expected CNS market share gains
- New product launches in India
- Rich valuation (68.6x P/E vs. 31.77x industry)
- Promoter selling (down 24.16%)
- Negative free cash flow (₹-189.53 Cr over 5 years)
Promoter is dumping shares; FII/DII holdings unchanged.
General India 2026: No specific macro headwinds or tailwinds identified.
Rubicon acquiring 85% stake in Arinna Lifesciences for ₹175.92 crore.
No (Free Cash Flow 5Y: ₹-189.53 Cr)
3-6 month thesis: Hope for seamless integration and CNS market gains. Reality: Valuation correction and promoter selling pressure.
Primary Thesis Risk
Promoter selling signals lack of confidence and impending valuation collapse.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Rubicon Research Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Rubicon Research Fundamental Analysis & Valuation Benchmarking
Educational evaluation of RUBICON across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (29.02%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (26.16%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.50%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Robust Profit Growth (56.18%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (39.19%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Consistent Growth Track Record (37.32% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (22.95% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Strong Interest Coverage (6.29x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (59.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Premium Valuation Risk (P/E: 68.60x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Weak Earnings Growth (-37.89% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-189.53 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Rubicon Research vs Pharmaceuticals Peers
Peer Comparison -
Compare Rubicon Research with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Rubicon ResearchRubicon Researc...Selected✓ RUBICON • 544578 | 44.2/100 | ₹1302.60₹1303 | ₹10546.51₹10546.51 | 68.60Average 68.6 Average | 29.02%Excellent 29.02% Excellent | 26.16%Excellent 26.16% Excellent | 0.88Good 0.9 Good | 22.95%Excellent 22.95% Excellent | 37.32%Excellent 37.32% Excellent | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Rubicon Research Quarterly Performance
Latest quarterly metrics for RUBICON — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
39.19%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
56.18%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
37.32%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
22.95%
Compounded annual net profit growth over 5 years
Rubicon Research Technical Indicators
SMA 50, SMA 200, RSI and volume signals for RUBICON — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Rubicon Research Financial Statements
Annual income statement, balance sheet and cash flow for Rubicon Research (RUBICON) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Rubicon Research
About RUBICON (Rubicon Research)
Rubicon Research (RUBICON) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a curren...t market capitalisation of ₹10.55K (Cr). Rubicon Research has delivered a Return on Equity (ROE) of 29.02% and a ROCE of 26.16%. The debt-to-equity ratio stands at 0.88, reflecting the company's capital structure. Investors tracking RUBICON share price can monitor key metrics including P/E ratio, promoter holding of 59.99%, and quarterly earnings growth.
Company Details
RUBICON Share Price: Frequently Asked Questions
What is the current share price of Rubicon Research?
Rubicon Research (RUBICON) trades at ₹1302.60 on NSE and BSE. Market cap ₹10.55K (Cr). Educational data only.
What is the P/E ratio of Rubicon Research?
Rubicon Research has a P/E of 68.60x vs industry average 31.77x.
What is the Bull Run score for Rubicon Research?
Rubicon Research has a Bull Run score of 44.2/100 based on 25+ financial parameters.
Does Rubicon Research pay dividends?
Rubicon Research has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Rubicon Research?
Rubicon Research has ROE of 29.02%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Rubicon Research?
Rubicon Research has debt-to-equity of 0.88.
Is Rubicon Research a good investment?
Bull Run gives Rubicon Research a score of 44.2/100. This is not investment advice — consult a SEBI-registered advisor.